基于WHO胰胆细胞病理报告系统的胆道细胞学恶性风险
该回顾性研究纳入1056例胆道细胞学病例(789例患者),按WHO胰胆细胞病理分类评估恶性风险(ROM)。胆道刷检/冲洗和FNA的绝对ROM在WHO I至III类较高,高级别(V-VII)类别恶性比值比显著升高。低级别病变罕见阻碍了Pan-low(WHO IV)的ROM评估,Pan-high(WHO V)的临床价值因高级别非浸润性病变罕见和细胞学诊断困难而不确定。
要点
- 胆道细胞学WHO I-III类的绝对恶性风险较高,部分因取样困难。
- 高级别(V-VII)类别无论活检方式、支架或自身免疫性胆管炎,恶性比值比均显著升高。
- Pan-low(WHO IV)和Pan-high(WHO V)的ROM评估受限,临床价值待明确。
核心结论
- 胆道病变WHO I至III类的绝对恶性风险较高,部分因取样癌症困难,尤其是外压性梗阻胆管者。
- 低级别胆道病变罕见,阻碍Pan-low(WHO IV)的绝对恶性风险评估。
- Pan-high(WHO V)的临床价值因高级别非浸润性病变罕见和细胞学诊断困难而不确定。
研究设计与样本
- 回顾性收集2016至2019年诊断的胆道细胞学数据,共1056例(来自789例患者)。
- 样本类型:胆道刷检/冲洗757例(72%),FNA 115例(11%),其他184例(17%)。
- 同部位组织学对照292例(28%),转移灶组织学124例(12%)。
- 排除无组织学且临床随访不足3个月的病例后,计算ROM、比值比、性能特征和总生存。
主要发现
- 789例患者中704例(89%)出现恶性结局。
- 胆道刷检/冲洗的WHO I至VII类绝对ROM分别为92%、72%、87%、0%、100%、94%、100%。
- FNA的WHO I至VII类绝对ROM分别为50%、46%、73%、不适用、100%、80%、100%。
- 良性病例中位随访1431天。
关键数值与推荐
- 高级别(V-VII)类别无论活检方式、支架存在或自身免疫性胆管炎,恶性比值比均显著升高。
- 胆道刷检/冲洗WHO I至VII类绝对ROM:92%、72%、87%、0%、100%、94%、100%。
- FNA WHO I至VII类绝对ROM:50%、46%、73%、不适用、100%、80%、100%。
临床怎么用
- 胆道细胞学报告应采用WHO胰胆分类系统,明确ROM分层。
- 高级别(V-VII)类别提示恶性风险显著增高,应结合临床积极处理。
- Pan-low(WHO IV)因病变罕见,ROM评估需谨慎,避免过度解读。
局限性
- 低级别胆道病变罕见,限制Pan-low(WHO IV)的ROM评估。
- 高级别非浸润性病变罕见且细胞学诊断困难,Pan-high(WHO V)临床价值不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The World Health Organization (WHO) classification for pancreaticobiliary cytopathology stratifies risk of malignancy (ROM) and outcome for pancreatic fine-needle aspirations (FNAs). ROM for biliary cytology, particularly for WHO categories Pan-low (IV) and Pan-high (V), has not been well examined. METHODS: Retrospective data of biliary cytology diagnosed from 2016 to 2019 were collected. WHO classification was assigned. Malignant outcome was determined by histologic correlation or clinical progression/death. Excluding clinical follow-up <3 months (if no histology), the ROM, odds ratio, performance characteristics, and overall survival were calculated. RESULTS: A total of 1056 biliary cytology cases (from 789 patients) were included. Sample types were: 757 (72%) biliary brush/wash, 115 (11%) FNA, and 184 (17%) other. Same-site histologic correlation was 292 (28%) and histology of metastasis in 124 (12%). The median follow-up (for benign) was 1431 days. Malignant outcome occurred in 704 (n = 789, 89%) of patients. Absolute ROM (%) for WHO I to VII by biliary brush/wash and FNA were: 92, 72, 87, 0, 100, 94, 100, and 50, 46, 73, N/A, 100, 80, 100, respectively. A high-tier (V-VII) category had significantly higher odds of malignancy regardless of biopsy modality, presence of stent, or autoimmune cholangitis. CONCLUSION: Absolute ROM for biliary lesions is high for WHO I through III and is at least partly because of difficulty in sampling cancers, particularly those extrinsically obstructing the bile duct. The rarity of low-grade biliary lesions impedes AROM assessment for Pan-low (WHO IV). The clinical value of biliary Pan-high (WHO V) remains uncertain because of rarity of high-grade noninvasive lesions and difficulty in cytology diagnosis.
引用
- Abraham AE, Wang X, Hargett I, et al. Risk of malignancy for biliary cytology based on World Health Organization (WHO) reporting system for pancreaticobiliary cytopathology. Cancer Cytopathol. 2026. PMID: 42142111. doi:10.1002/cncy.70109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。